摘要
Background: Past research has found that fibroblast growth factor 19 (FGF19) is associated with several hepatic disorders, such as alcoholic liver disease and primary biliary cirrhosis. However, there is currently a lack of relevant studies on the relationship between FGF19 and hepatitis B virus (HBV)-related liver disease. @@@ Objectives: This study aimed to assess the role of serum FGF19 as anewbiomarker for HBV-related liver disease and provide scientific data to show the clinical value of this biomarker. @@@ Methods: A retrospective study included 37 patients with chronic hepatitis B (CHB), 33 patients with HBV-related cirrhosis (HBVcirrhosis), and 32 patients with HBV-related hepatocellular carcinoma (HBV-HCC). Furthermore, 33 normal people were randomly selected as healthy controls. The serum levels of FGF19 were measured by ELISA. @@@ Results: Serum FGF19 levels were increased sequentially in the CHB group, HBV-cirrhosis group, and HBV-HCC group. Furthermore, serum FGF19 levels positively correlated with alpha-fetoprotein, prothrombin time, international normalized ratio, total bilirubin, direct bilirubin, alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl-transferase, alkaline phosphatase, total bile acid, serum markers for liver fibrosis, ascites, cirrhosis, Child-Pugh classification and model for end-stage liver disease sodium (MELD-Na) score, while negatively correlated with platelet count, prothrombin activity, and albumin. The diagnostic threshold of serum FGF19 for HBV-related HCC was 165.32 pg/mL, with a sensitivity of 81.25% and specificity of 58.57%. @@@ Conclusions: Serum FGF19 levels are positively associated with cholestasis, hepatocyte damage, and liver fibrosis but negatively correlated with liver synthetic function and liver functional reserve in HBV-related liver disease. Diverse changes in serum FGF19 may be used as a predictive marker for the progression of HBV-related liver disease. In addition, serum FGF19 has a potential role in monitoring carcinogenesis in patients with HBV-related liver disease.
学科与关键词
- Association between immunologic markers and cirrhosis in individuals with chronic hepatitis BArgirion, Ilona*; Pfeiffer, Ruth M.; Lam, Tram Kim; O'Brien, Thomas R.; Yu, Kelly; McGlynn, Katherine A.; Petrick, Jessica L.; Pinto, Ligia; Chen, Chien-Jen; Lee, Mei-Hsuan; Hildesheim, Allan; Yang, Hwai-, I; Koshiol, Jill2021, 11(1): 21194.
- Relationship between hepatitis B surface antigen, HBV DNA quantity and liver fibrosis severity郜玉峰; 邹桂舟; 叶珺; 潘高峰; 饶建国; 李芳; 魏艳艳; 李旭2015.
- CXCL8, CXCL9, CXCL10, and CXCL11 as biomarkers of liver injury caused by chronic hepatitis BYu, Xin; Chen, Ying; Cui, Lele; Yang, Kaming; Wang, Xumeng; Lei, Linyuan; Zhang, Yanping; Kong, Xinyi; Lao, Wanwen; Li, Zhenlin; Liu, Yang; Li, Yuetong; Bi, Changlong*; Wu, Chao*; Zhai, Aixia*Frontiers in Microbiology, 2022, 13: 1052917.被引 6
